Tema ETFs LLC Acquires 3,956 Shares of AbbVie Inc. $ABBV

Tema ETFs LLC lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 6.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 61,759 shares of the company’s stock after purchasing an additional 3,956 shares during the quarter. Tema ETFs LLC’s holdings in AbbVie were worth $15,541,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Haven Capital Group Inc. increased its position in AbbVie by 1.3% during the second quarter. Haven Capital Group Inc. now owns 22,119 shares of the company’s stock worth $5,566,000 after buying an additional 280 shares during the last quarter. Peirce Capital Management LLC acquired a new stake in shares of AbbVie in the second quarter worth about $220,000. Dagco Inc. lifted its position in shares of AbbVie by 13.2% in the second quarter. Dagco Inc. now owns 9,479 shares of the company’s stock worth $2,385,000 after buying an additional 1,107 shares during the last quarter. West Branch Capital LLC boosted its stake in shares of AbbVie by 0.6% during the 2nd quarter. West Branch Capital LLC now owns 30,433 shares of the company’s stock worth $7,658,000 after acquiring an additional 173 shares in the last quarter. Finally, Canvas Wealth Advisors LLC increased its holdings in shares of AbbVie by 21.5% during the 2nd quarter. Canvas Wealth Advisors LLC now owns 2,605 shares of the company’s stock valued at $656,000 after acquiring an additional 461 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Apogee Therapeutics shareholders approved AbbVie’s approximately $10.9 billion cash acquisition, helping remove a key closing hurdle. The deal is expected to expand AbbVie’s immunology pipeline with zumilokibart, an atopic dermatitis candidate advancing toward Phase 3 trials, while Apogee’s leadership transition is expected to support integration. Apogee Shareholders Approve AbbVie Acquisition and Leadership Transition
• Positive Sentiment: AbbVie’s Skyrizi and Rinvoq continued to drive strong quarterly growth through market-share gains and additional indications, reinforcing the company’s strategy for replacing revenue eventually pressured by Humira biosimilars. How Much Did Immunology Drugs Contribute to AbbVie’s Q2 Performance?
• Positive Sentiment: The FDA accepted a supplemental application to review Botox Cosmetic for treating masseter muscle prominence. Approval would create a potential fifth use for the brand and modestly broaden AbbVie’s aesthetics growth opportunity. AbbVie’s Botox Just Got A Step Closer To A Fifth Use
• Neutral Sentiment: BNP Paribas Exane raised its ABBV price target from $218 to $247 but maintained a Neutral rating, suggesting limited upside after the recent rally. BNP Paribas Exane AbbVie Price Target Update
• Neutral Sentiment: Investor commentary remains constructive on AbbVie’s dividend and valuation, with some analysts describing the stock as an attractive income-oriented healthcare investment after its solid second-quarter performance. Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?
• Negative Sentiment: AbbVie is reportedly taking on roughly $8 billion of debt to help fund the Apogee transaction. While the acquisition could strengthen long-term growth, added leverage may increase interest costs and concern dividend investors if expected pipeline returns take longer to materialize. AbbVie Piles on $8 Billion in Debt for Its Apogee Deal
• Negative Sentiment: Erste Group Bank trimmed its FY2027 EPS forecast from $16.40 to $16.24, although it retained a Buy rating. The revision is a modest headwind amid ABBV’s elevated price-to-earnings multiple.

AbbVie Trading Up 0.7%

ABBV opened at $249.73 on Wednesday. The business has a 50 day moving average of $243.35 and a 200-day moving average of $225.51. The stock has a market capitalization of $441.22 billion, a price-to-earnings ratio of 70.54, a P/E/G ratio of 0.82 and a beta of 0.30. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the previous year, the firm posted $2.97 earnings per share. AbbVie’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts predict that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ABBV. JPMorgan Chase & Co. raised their price objective on AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Royal Bank Of Canada increased their price target on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. UBS Group lifted their price target on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Monday, July 13th. Morgan Stanley restated an “overweight” rating and issued a $296.00 price objective on shares of AbbVie in a research note on Monday, August 3rd. Finally, Piper Sandler reiterated an “overweight” rating and issued a $298.00 target price on shares of AbbVie in a research note on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $274.33.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.